People · Operator
Named in public records as an officer, director or promoter · active 2011–2018 · Biotechnology, Pharmaceuticals, Software / Tech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Osmol Therapeutics, Inc. | — | Biotechnology | Seed | $2.9M | $41.6M | 2016 |
| Occam Sciences, Inc. | — | Pharmaceuticals | Pre-Seed | $300K | $14.2M | 2011 |
| D Plug Software Inc. | — | Software / Tech | Pre-Seed | $250K | $10.6M | 2018 |
Brian Dixon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Dixon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Berman | 1 | 4 |
| John Warner | 1 | 3 |
| Vlad Coric | 1 | 2 |
| Robert Bettigole | 1 | 2 |
| Robert Linke | 1 | 2 |
| Brandon Dixon | 1 | 1 |
| Michael Burgos | 1 | 1 |
| Merton G. Gollaher | 1 | 1 |
| Joseph Pont | 1 | 1 |
| David Whittaker | 1 | 1 |
| Michael Ehrlich | 1 | 1 |
| Christopher Denis | 1 | 1 |
| Jean Paul | 1 | 1 |
| Haider Rana | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.